Suggested remit: To appraise the clinical and cost effectiveness of dabigatran etexilate within its marketing authorisation for the secondary prevention of stroke in people who have had an embolic stroke of undetermined source.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- None selected
- Process:
- STA Standard
- ID number:
- 1417
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 November 2018 | The National Institute for Health and Care Excellence (NICE) has been invited to consider and appraisal of dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source ID 1417. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets dabigatran etexilate has advised that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information the Institute will not be progressing with the scoping exercise. If you have any comments or concerns please contact the project manager for this appraisal via email at [email protected] |
For further information on our processes and methods, please see our CHTE processes and methods manual